PDCD1 and melanoma: Previous studies using the Rho/MRTF pathway inhibitor CCG-257081 and related analogs showed promising outcomes in reducing melanoma metastasis (Haak et al., 2017), enhancing sensitivity to targeted therapies (Haak et al., 2017; Lionarons et al., 2019; Appleton et al., 2021; Foda and Neubig, 2023), and enhancing immune responses to anti-PD1 immune checkpoint therapy (Foda et al., 2024).